Pfizer looks to expand ADC use after positive bladder cancer data
Written by
BioPharma Dive
Published
0
comments
0
min
Padcev, an antibody-drug conjugate which Pfizer acquired via its $43 billion Seagen deal, could help people who don’t qualify for chemotherapy.